Researchers at Hammersmith Hospital in London have developed new drug, PEGylated-interferon, to treat hepatitis C patients that will save the NHS hundreds of millions of pounds a year. It costs just a fraction of that spent on current treatment and will make therapy affordable for millions of sufferers worldwide.
The new drug was developed by researchers from Hammersmith Hospital working in conjunction with scientists from Imperial College, the London School of Pharmacy and colleagues in India. Clinical trials will start in India next year.